Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novocure Launches INNOVATE 3 Trial Of Ovarian Cancer Therapy

Executive Summary

INNOVATE 3 is a phase 3 pivotal trial testing the efficacy of Novocure's Tumor Treating Fields therapy combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

You may also be interested in...



Higher Doses Of Novocure’s TTF Help New Glioblastoma Patients

The first reported analysis demonstrating a patient-level dose response with Novocure’s Tumor Treating Fields therapy is now published. The post-hoc analysis of the EF-14 trial showed higher doses of Tumor Treating Fields improved survival in newly diagnosed glioblastoma patients.

NovoCure’s Tumor Treating Fields Help Mesothelioma Patients Live Longer In STELLAR Trial

New results from the Phase II STELLAR trial shows Tumor Treating Fields therapy in conjunction with chemotherapy extends survival in previously untreated mesothelioma patients with no safety problems.

Results Recap: Long-Term Results Support NovoCure's Optune Brain-Cancer Technology

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 30 – Dec. 6, includes results of a retrospective post-hoc sub-group analysis of the EF-14 phase III pivotal trial of Novocare's Optune system in newly diagnosed glioblastoma, one-year data from a study of Vieve Medical's Geneveve treatment of mild-to-moderate stress urinary incontinence, and complete results from the Long-Term Treatment Study of NeuroPace's RNS system to treat epileptic seizures.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel